Squarepoint
VKTX icon

Squarepoint’s Viking Therapeutics VKTX Stock Holding History

Squarepoint’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Buy
+41,139
New +$1.33M ﹤0.01% 2512
2025
Q3 		– Sell
-55,355
Closed -$1.65M – 5052
2025
Q2 		$1.47M Sell
55,355
-383,576
-87% -$10.1M ﹤0.01% 2330
2025
Q1 		$10.6M Buy
438,931
+171,626
+64% +$5.42M 0.01% 995
2024
Q4 		$10.8M Buy
267,305
+233,051
+680% +$13.3M 0.01% 1105
2024
Q3 		$2.17M Sell
34,254
-107,566
-76% -$6.31M ﹤0.01% 2011
2024
Q2 		$7.52M Buy
+141,820
New +$9.3M 0.01% 1106
2024
Q1 		– Sell
-50,603
Closed -$942K – 4654
2023
Q4 		$942K Buy
50,603
+23,673
+88% +$310K ﹤0.01% 2561
2023
Q3 		$298K Buy
+26,930
New +$385K ﹤0.01% 3171
2023
Q2 		– Sell
-26,063
Closed -$434K – 4052
2023
Q1 		$434K Buy
+26,063
New +$269K ﹤0.01% 2384
2022
Q4 		– Sell
-14,382
Closed -$39K – 3633
2022
Q3 		$39K Sell
14,382
-381
-3% -$1.25K ﹤0.01% 2879
2022
Q2 		$43K Sell
14,763
-3,077
-17% -$7.62K ﹤0.01% 2721
2022
Q1 		$54K Sell
17,840
-50,279
-74% -$180K ﹤0.01% 2674
2021
Q4 		$313K Buy
68,119
+37,704
+124% +$211K ﹤0.01% 2424
2021
Q3 		$191K Sell
30,415
-68,751
-69% -$425K ﹤0.01% 2511
2021
Q2 		$594K Sell
99,166
-7,089
-7% -$42.1K ﹤0.01% 2016
2021
Q1 		$672K Buy
106,255
+61,907
+140% +$436K ﹤0.01% 1806
2020
Q4 		$250K Sell
44,348
-55,336
-56% -$335K ﹤0.01% 2359
2020
Q3 		$580K Buy
+99,684
New +$686K 0.01% 1319
2020
Q1 		– Sell
-110,347
Closed -$885K – 2559
2019
Q4 		$885K Buy
110,347
+29,868
+37% +$218K 0.01% 1414
2019
Q3 		$554K Sell
80,479
-55,239
-41% -$410K ﹤0.01% 1565
2019
Q2 		$1.13M Buy
135,718
+85,118
+168% +$727K 0.01% 1194
2019
Q1 		$503K Sell
50,600
-25,343
-33% -$212K 0.01% 1484
2018
Q4 		$581K Buy
+75,943
New +$908K 0.01% 1171

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Squarepoint's VKTX Position: Q2 2026 in Review

Squarepoint opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 41,139 shares worth $1.6M. The stake represents ﹤0.01% of the portfolio and ranks #2512 among its holdings. This is a return to the name: Squarepoint previously reported a position in VKTX as recently as Q2 2025.

Squarepoint first reported a position in VKTX in Q4 2018 and has held it in 23 quarters since. The position peaked at $10.8M in Q4 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Squarepoint held 41,139 shares of Viking Therapeutics worth $1.6M as of Q2 2026.
  • Viking Therapeutics was a new Squarepoint position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2512 holding.
  • Squarepoint first reported a position in Viking Therapeutics in Q4 2018 and has held it in 23 quarters since.
  • Squarepoint's Viking Therapeutics position peaked at $10.8M in Q4 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.